Pfizer Sees Celebrex Script Growth In Days Following Bextra Withdrawal
This article was originally published in The Tan Sheet
Executive Summary
Pfizer is seeing an increase in Celebrex prescriptions in the days following the withdrawal of its other COX-2 inhibitor, Bextra, the company said April 19